Dr. James Peyer is founder and CEO of Cambrian Bio. James has spent two decades working to bring the first longevity drug to market. In this time, he’s brought over $500M into the field as a whole, and now has multiple drugs in clinical trials that could plausibly prove to be… the first true longevity drugs, or gerotherapeutics.

In today’s episode, we dive into the history of the geroscience field. We discuss what makes geroscience’s approach to drug development so unique, how to unlock the flywheel of innovation that will get us longevity escape velocity, and Amplifier Therapeutics' “zone 2 in a pill”... which might prove to be the first ever true, longevity drug.

Nathan Cheng is an activist who has dedicated his life and career to defeating aging and death. After going through an existential crisis and dropping out of a Physics PhD, Nathan discovered the longevity movement and became one of the most prolific activists in the space. He is a founder of Longevity Biotech Fellowship, Vitalism Foundation, Longevity List, Longevity Marketcap and a General Partner at Healthspan Capital.

In this conversation, we reflect on the absurdity of questioning people like Nathan why they choose to dedicate themselves to fighting aging (when it’s the thing that kills over 100k people per day), why longevity is underinvested into, and much more.

Resources:

• Longevity Biotech Fellowship: https://www.longbiofellowship.org/

• Vitalism: vitalism.io

• Join us at Vitalist Bay! vitalistbay.com

Today’s guest is Kexin Huang. Kexin recently raised $13.5M from Andreessen Horowitz and Menlo Ventures in partnership with Anthropic, to build Phylo - a research lab studying agentic biology. Phylo’s first product is Biomni, the world’s first open source IBE or Integrated Biology Environment for conducting agentic biology research. They intend to do for biology what the IDE did for software.

Kexin completed his PhD in Computer Science at Stanford, where he was advised by Jure Leskovec on artificial intelligence for healthcare and biology. As a PhD student Kexin garnered over 10,000 citations, published in Nature and earned six best paper awards at leading machine learning conferences, all this before the age of 30.

Kexin has earned a reputation as one of the brightest minds in AI for life sciences. You’ll see why in today’s conversation.